CD44 and cancer: Here, by coupling aptamer-based affinity purification and subsequent mass spectrometry (MS)-based proteomics with a systematic approach that takes advantage of the different binding affinity of sTN58 to different cancer cell lines, we succeeded in identifying CD44 as the target of sTN58.